• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avantor® Appoints Simon Dingemans to its Board of Directors

    12/18/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email

    RADNOR, Pa., Dec. 18, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Simon Dingemans to its Board of Directors, effective January 2, 2026.

    Avantor. Setting science in motion to create a better world. (PRNewsfoto/Avantor)

    Mr. Dingemans is an accomplished executive with extensive global leadership experience across healthcare, finance and strategic business transformation. He was previously the Chief Financial Officer of GlaxoSmithKline plc, a Partner at Goldman Sachs, and a Managing Director at The Carlyle Group. He currently serves on the boards of Vodafone Group Plc and WPP plc.

    "The Board continues to take action to accelerate growth and profitability at Avantor," said Gregory Summe, incoming Chairman of the Avantor board. "With Simon's breadth of experience guiding complex global organizations and his background in operational transformation, financial discipline and strategic execution, he is well suited to help advance the Avantor Revival plan. Simon's appointment demonstrates the Board's commitment to finding the best talent to help create value for our stakeholders."

    "Avantor's innovative products and services have made the Company a trusted partner to the scientific community across the globe," said Mr. Dingemans. "I look forward to supporting the Company's efforts to drive operational improvements, deepen customer partnerships and position Avantor for sustainable, long-term success."

    About Simon Dingemans

    Simon Dingemans is an accomplished business leader with significant experience guiding large global organizations through complex financial, operational and strategic initiatives. During his tenure as Chief Financial Officer of GlaxoSmithKline plc, he led major business services and technology modernization programs, oversaw capital allocation and financial operations, and supported strategic transactions that helped reshape the company's portfolio. He currently serves on the Boards of Vodafone Group Plc, WPP plc and Genomics LTD, where he is also non-executive Chair.

    Earlier in his career, Mr. Dingemans held senior leadership positions at Goldman Sachs International, where he oversaw UK investment banking and European mergers activity, and later served in senior advisory and operating roles at The Carlyle Group. He holds both a bachelor's degree and a master's degree in geography from the University of Oxford.

    About Avantor

    Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.

    Forward-Looking and Cautionary Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, including our cost transformation initiative, objectives, future performance and business. These statements may be preceded by, followed by or include the words "aim," "anticipate," "assumption," "believe," "continue," "estimate," "expect," "forecast," "goal," "guidance," "intend," "likely," "long-term," "near-term," "objective," "opportunity," "outlook," "plan," "potential," "project," "projection," "prospects," "seek," "target," "trend," "can," "could," "may," "should," "would," "will," the negatives thereof and other words and terms of similar meaning.

    Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. Factors that could contribute to these risks, uncertainties and assumptions include, but are not limited to, the factors described in "Risk Factors" in our most recent Annual Report on Form 10-K, and subsequent quarterly reports on Form 10-Q, as such risk factors may be updated from time to time in our periodic filings with the SEC.

    All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.

    Investor Relations Contact

    Allison Hosak

    Senior Vice President, Global Communications

    Avantor

    908-329-7281

    [email protected]

    Media Contact

    Eric Van Zanten

    Head of External Communications

    Avantor

    610-529-6219

    [email protected] 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-appoints-simon-dingemans-to-its-board-of-directors-302645172.html

    SOURCE Avantor and Financial News

    Get the next $AVTR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    12/17/2025$9.00Hold → Underperform
    Jefferies
    12/15/2025$13.00Buy → Neutral
    BofA Securities
    11/4/2025Outperform → Mkt Perform
    Raymond James
    10/30/2025$12.00Overweight → Equal Weight
    Barclays
    10/30/2025$12.00Overweight → Neutral
    Analyst
    8/1/2025Buy → Hold
    Jefferies
    4/29/2025$14.00Buy → Neutral
    Goldman
    4/28/2025$15.50Buy → Hold
    TD Cowen
    More analyst ratings

    $AVTR
    SEC Filings

    View All

    Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    12/18/25 8:17:12 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    12/4/25 4:29:41 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    11/10/25 5:11:45 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avantor® Appoints Simon Dingemans to its Board of Directors

    RADNOR, Pa., Dec. 18, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Simon Dingemans to its Board of Directors, effective January 2, 2026. Mr. Dingemans is an accomplished executive with extensive global leadership experience across healthcare, finance and strategic business transformation. He was previously the Chief Financial Officer of GlaxoSmithKline plc, a Partner at Goldman Sachs, and a Managing Dire

    12/18/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Sanjeev Mehra to its Board of Directors

    RADNOR, Pa., Dec. 4, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Sanjeev Mehra to its Board of Directors, effective immediately.   Mr. Mehra is Co-Founder and serves as Managing Partner of Periphas Capital LP, a private equity firm focused on investing in technology enabled businesses in services, consumer and industrial end markets. Prior to founding Periphas, Mr. Mehra spent over 30 years at Goldman,

    12/4/25 4:15:00 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Receives 2025 Edison Patent Award for Sustainable Viral Inactivation Technology

    Research & Development Council of New Jersey honors Avantor for developing a biodegradable detergent solution that advances safe, sustainable biomanufacturing RADNOR, Pa., Nov. 25, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the Company, in partnership with Amgen, received a 2025 Edison Patent Award from the Research & Development Council of New Jersey. The recognition was for their pioneering development of a biodegradable detergent that enables safer, more sustainable viral inactivation in biomanufacturing. Co-developed by Avantor

    11/25/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mehra Sanjeev K was granted 8,106 shares and bought $3,881,500 worth of shares (350,000 units at $11.09) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    12/9/25 5:11:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Ligner Emmanuel bought $993,125 worth of shares (87,500 units at $11.35), increasing direct ownership by 45% to 283,424 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    11/17/25 5:45:30 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $1,125,000 worth of shares (100,000 units at $11.25) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    10/31/25 9:46:22 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mehra Sanjeev K was granted 8,106 shares and bought $3,881,500 worth of shares (350,000 units at $11.09) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    12/9/25 5:11:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Mehra Sanjeev K

    3 - Avantor, Inc. (0001722482) (Issuer)

    12/9/25 5:07:43 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Ligner Emmanuel bought $993,125 worth of shares (87,500 units at $11.35), increasing direct ownership by 45% to 283,424 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    11/17/25 5:45:30 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Avantor downgraded by Jefferies with a new price target

    Jefferies downgraded Avantor from Hold to Underperform and set a new price target of $9.00

    12/17/25 8:49:45 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by BofA Securities with a new price target

    BofA Securities downgraded Avantor from Buy to Neutral and set a new price target of $13.00

    12/15/25 9:53:32 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Raymond James

    Raymond James downgraded Avantor from Outperform to Mkt Perform

    11/4/25 7:41:39 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Leadership Updates

    Live Leadership Updates

    View All

    Avantor® Appoints Simon Dingemans to its Board of Directors

    RADNOR, Pa., Dec. 18, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Simon Dingemans to its Board of Directors, effective January 2, 2026. Mr. Dingemans is an accomplished executive with extensive global leadership experience across healthcare, finance and strategic business transformation. He was previously the Chief Financial Officer of GlaxoSmithKline plc, a Partner at Goldman Sachs, and a Managing Dire

    12/18/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Sanjeev Mehra to its Board of Directors

    RADNOR, Pa., Dec. 4, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Sanjeev Mehra to its Board of Directors, effective immediately.   Mr. Mehra is Co-Founder and serves as Managing Partner of Periphas Capital LP, a private equity firm focused on investing in technology enabled businesses in services, consumer and industrial end markets. Prior to founding Periphas, Mr. Mehra spent over 30 years at Goldman,

    12/4/25 4:15:00 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Mary Blenn as Executive Vice President and Chief Operating Officer

    RADNOR, Pa., Nov. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced that Mary Blenn has been appointed to the newly created role of Executive Vice President and Chief Operating Officer, effective immediately. Ms. Blenn will report to President and CEO Emmanuel Ligner and will lead the Company's manufacturing and supply chain operations. She will be responsible for aligning Avantor's manufacturing and logistics network wit

    11/10/25 8:30:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    11/14/24 1:28:33 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/9/24 3:22:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/7/24 4:09:12 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Financials

    Live finance-specific insights

    View All

    Avantor® Reports Third Quarter 2025 Results

    Net sales of $1.62 billion, decrease of 5%Net loss of $712 million and diluted GAAP loss per share of $1.04, including a non-cash goodwill impairment charge of $785 millionAdjusted EBITDA of $268 million; adjusted EPS of $0.22Operating cash flow of $207 million; free cash flow of $172 millionCompany announces $500 million share repurchase authorization, reflecting confidence in cash generation and commitment to driving long-term shareholder valueRADNOR, Pa., Oct. 29, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its t

    10/29/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Host Third Quarter 2025 Earnings Call on Wednesday, October 29, 2025

    RADNOR, Pa., Oct. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its third quarter 2025 financial results before the market opens on Wednesday, October 29, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days. About AvantorAvantor® is a leading life science tools company and global

    10/1/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports Second Quarter 2025 Results

    Net sales of $1.68 billion, decrease of 1%; organic revenue was flatNet income of $65 million; Adjusted EBITDA of $280 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.24Operating cash flow of $154 million; free cash flow of $125 millionRADNOR, Pa., Aug. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2025. "In the second quarter, we remained focused on driv

    8/1/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials